Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
June 16, 2021

Coronavirus company news summary – Actim’s SARS-CoV-2 rapid test receives CE mark approval – ALBOT to develop and distribute CRISPR Covid-19 diagnostic kits in India

By Chloe Kent

Biodesix, a diagnostic solutions company, has announced the commercial launch of a SARS CoV-2 neutralisation antibody test, the cPass neutralisation test kit. The test uses ELISA technology to detect circulating neutralising antibodies produced in response to a Covid-19 vaccine and infection. It is the first and only surrogate neutralising antibody test to have received Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA).

Actim, a Finnish-based diagnostics company, recently received a CE mark for its new easy-to-use rapid antigen test for detecting acute Covid-19 infection in minutes. Intended for healthcare professionals only, the test identifies the infection in nasopharyngeal swab samples without the need for laboratory equipment. It has proven high reliability in diagnosing different Covid-19 variants.

The 221b Foundation, a non-profit organisation established by biotechnology company Sherlock Biosciences, has granted a license to ALBOT USA and ALBOT Technologies Private Limited India to develop, manufacture and distribute Covid-19 diagnostic tests utilising Sherlock’s CRISPR technology. ALBOT can produce approximately 30,000 test kits per day, which will be distributed across government laboratories and facilities to meet the diagnostic testing needs of all regions.

Related Companies

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU